Table 3 Distributions of the eNOS3 864G/T and IL-1β 315C/T alleles and genotypes in the CSFP and control groups
| Â | Patients With CSFP; N (%) | Controls; N (%) | OR (95% CI)b | P valuea |
|---|---|---|---|---|
eNOS 894G/T | Â | Â | Â | Â |
Allele Frequency | Â | Â | Â | Â |
 G | 287 (80) | 124 (71) | 1.00 | 0.03 |
 T | 73 (20) | 50 (29) | 1.58 (1.04–2.42) |  |
 Total | 360 (100) | 174 (100) |  |  |
Genotypes (codominant) | Â | Â | Â | Â |
 G/G | 117 (65) | 45 (51.7) | 1.00 | 0.11 |
 G/T | 53 (29.4) | 34 (39.1) | 0.60 (0.35–1.04) |  |
 T/T | 10 (5.6) | 8 (9.2) | 0.48 (0.18–1.30) |  |
 Total | 180 (100) | 87 (100) |  |  |
Genotypes (dominant) | Â | Â | Â | Â |
 G/G | 117 (65) | 45 (51.7) | 1.00 | 0.04 |
 G/T-T/T | 63 (35) | 42 (48.3) | 1.73 (1.02–2.95) |  |
Genotypes (recessive) | Â | Â | Â | Â |
 G/G-G/T | 170 (94.4) | 79 (90.8) | 1.00 | 0.27 |
 T/T | 10 (5.6) | 8 (9.2) | 1.72 (0.66–4.68) |  |
HWEc | X2 = 1.484, P = 0.48 | X2 = 0.1867, P = 0.91 |  |  |
IL-1β 315C/T |  |  |  |  |
Allele Frequency | Â | Â | Â | Â |
 C | 269 (76) | 130 (75) | 1.00 | 0.83 |
 T | 87 (24) | 44 (25) | 1.047 (0.68–1.59) |  |
 Total | 356 (100) | 174 (100) |  |  |
Genotype(codominant) | Â | Â | Â | Â |
 C/C | 103 (57.9) | 53 (60.9) | 1.00 | 0.25 |
 C/T | 63 (35.4) | 24 (27.6) | 1.73 (0.84–3.56) |  |
 T/T | 12 (6.7) | 10 (11.5) | 0.81 (0.26–2.52) |  |
 Total | 178 (100) | 87 (100) |  |  |
Genotype(dominant) | Â | Â | Â | Â |
 C/C | 103 (57.9) | 53 (60.9) | 1.00 | 0.63 |
 C/T-T/T | 75 (42.1) | 34 (39.1) | 0.881 (0.52–1.49) |  |
Genotype (recessive) | Â | Â | Â | Â |
 C/C–C/T | 166 (93.3) | 77 (88.5) | 1.00 | 0.19 |
 T/T | 12 (6.7) | 10 (11.5) | 1.797 (0.73–4.10) |  |
HWEc | X2 = 0.3557, P = 0.84 | X2 = 6.446, P = 0.04 |  |  |